Pulmonary disease in the cancer patient

  • John N. Landis
Part of the Cancer Treatment and Research book series (CTAR, volume 30)


Patients with cancer can develop numerous pulmonary problems during the management of their underlying disease. The spectrum of involvement can run from a totally unrelated pre-existing pulmonary process such as asthma or emphysema to complications of the primary cancer and its management. The major focus of this review is on common problems: diffuse infiltrative lung disease, pulmonary infection, and pleural effusions. This review should alert the clinician caring for the cancer patient to the possibilities of pulmonary involvement and the importance of establishing an early and definitive diagnosis if therapy is to be effective.


Pleural Effusion Pleural Fluid Malignant Mesothelioma Pleural Space Radiation Pneumonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Singer C, Armstrong D, Rosen PP, Walzer PD, Yu B. 1979. Diffuse pulmonary infiltrates in the immunosuppressed patient: Prospective study of 80 cases. Am J Med 66:110–120.PubMedCrossRefGoogle Scholar
  2. 2a.
    Williams DM, Krick JA, Remington JS. 1976. Pulmonary infection in the compromised host. Am Rev Respir Dis 114:359–394,PubMedGoogle Scholar
  3. 2b.
    Williams DM, Krick JA, Remington JS. 1976. Pulmonary infection in the compromised host. Am Rev Respir Dis 114: 593–627.PubMedGoogle Scholar
  4. 3.
    Burrows B, Earle RH. 1969. Course and prognosis of Chronic obstructive lung disease. NEJM 280:397–404.PubMedCrossRefGoogle Scholar
  5. 4.
    Demeter SL, Ahmad M, Tomaskefski JF. 1979. Drug induced pulmonary disease — I. Pat-Google Scholar
  6. 5.
    terns of response; II. Categories of drugs; III. Agents used to treat neoplasms or alter the immune system including a brief review of radiation therapy. Cleve Clin Q 46:89–99, 101–112, 113–124.Google Scholar
  7. 6.
    Samter M, Beers RF. 1968. Intolerances to aspirin: clinical studies in consideration of its pathogenesis. Ann Intern Med 68:975–983.PubMedCrossRefGoogle Scholar
  8. 7.
    Nash G: 1982. Pathologic features of the lung in the immunocopromised host. Hum Pathol 13:841–858.PubMedCrossRefGoogle Scholar
  9. 8.
    Holmes EC, Ramming KP, Eilber FR. 1977. Surgical management of pulmonary metastasis. Sem. Oncol 4:65–69.Google Scholar
  10. 9.
    Kessel L. 1959. Spontaneous disappearance of bilateral pulmonary metastases. Report of a case of adenocarcinoma of kidney after nephrectomy. JAMA 169:1737–1739.CrossRefGoogle Scholar
  11. 10.
    McCormack DM et al. 1978. Pulmonary resection in metastatic carcinoma. Chest 73:163–166.PubMedCrossRefGoogle Scholar
  12. 11.
    Janower ML, Blennerhassett JB. 1971. Lymphangitic spread of metastatic carcinoma of the lung. Diagn Radiol 101:267–273.CrossRefGoogle Scholar
  13. 12.
    Greenman RL, Goodall PT, D. 1975. Lung biopsy in immunocompromised hosts. Am J Med 59:488–496.PubMedCrossRefGoogle Scholar
  14. 13.
    Bode FR, Pare JA, Fraser RG. 1974. Pulmonary diseases in the compromised host: A review of clinical and roentgenographic manifestations in patients with impaires host defense mechanisms. Medicine (Baltimore) 53:255–293.CrossRefGoogle Scholar
  15. 14.
    Harlan JM, Fennessy JJ, Gross NJ. 1974. Bronchial brush biopsy in Hodgkin’s disease. Chest 66:136–138.PubMedCrossRefGoogle Scholar
  16. 15.
    Filly R, Blank N, Castellino RA. 1976. Radiographic distributions of intrathoracic disease in previously untreated patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Radiology 120:277–281.PubMedCrossRefGoogle Scholar
  17. 16.
    Whitcomb ME, Schwarz MI, Keller AR, Flannery EP, Blom J. 1972. Hodgkin’s disease of the lung. Am Rev Respir Dis 106:79–85.PubMedGoogle Scholar
  18. 17.
    Costello P, Mauch P. 1979. Radiographic features of recurrent intrathoracic Hodgkin’s disease following radiation therapy. Am J Roentgenol 133:201–206.CrossRefGoogle Scholar
  19. 18.
    Tenholder MF, hooper RG. 1980. Pulmonary infiltrates in leukemia. Chest 78:468–473.PubMedCrossRefGoogle Scholar
  20. 19.
    Bodey GP, Powell RD Jr, Hersh EM, Yeterian A, Freireich EJ. 1966. Pulmonary complications of acute leukemia. Cancer 19:781–793.PubMedCrossRefGoogle Scholar
  21. 20.
    Balducci L, Haibrook JC, Chappan SW, Vance RB, Thigpen JT, Morrison FS. 1983. Acute leukemia and infections: perspectives from a general hospital. Am j Hematol 15:57–63.PubMedCrossRefGoogle Scholar
  22. 21.
    Klatte EC, Yardley J, Smith EB, Röhn R, Campbell JA. 1963. The pulmonary manifestation and complications of leukemia. Am J Toentgentol 89:598–609.Google Scholar
  23. 22.
    Wardman AG, Milligan DW, Child JA, Delamore IW, Cooke NJ. 1984. Pulmonary infiltrates in adult acute leukemia: empirical treatment and survival related to the extent of pulmonary radiological disease. Thorax 39:568–571.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 23.
    Tenholder MF, Hooper RG. 1980. Pulmonary hemorhage in the immunocompromised host: An Elusive reality (Abstract). Am Rev Respir Dis 121 (Suppl):198.Google Scholar
  25. 24.
    Vernant JP, Brun B, Mannoni P, Dreyfus B. 1979. Respiratory disease of hyperleukocytic granulocytic leukemias. Cancer 44:264–268.PubMedCrossRefGoogle Scholar
  26. 25.
    McKee LC Jr, Collins RD. 1974. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicina (Baltimore) 53:463–478.CrossRefGoogle Scholar
  27. 26.
    Tryka AF, Godleski JJ, Fanta CH. 1982. Leukemic cell lysis pneumonopathy: A complication of treated myeloblastic leukemia. Cancer 50:2763–1770.PubMedCrossRefGoogle Scholar
  28. 27.
    Fowler AA, Hamman RF, Zerbe GO, Benson KN, Hyers TM. 1985. Prognosis after onset of adult repiratory distress syndrome. Am Rev Respir Dis 132:472–478.PubMedGoogle Scholar
  29. 28.
    Sostman Matthay RA, Putman CE. 1977. Cytotoxic drug induced lung disease. Am J Med 62:608–615.CrossRefGoogle Scholar
  30. 29.
    Ginsberg SJ, Comis RL. 1982. The pulmonary toxicity of antineoplastic agents. Sem Oncol 9:34–51.Google Scholar
  31. 30.
    Rosenow EC III. 1980. Chemotherapeutic drug induced pulmonary disease. Sem Respir Med 2:89–96.CrossRefGoogle Scholar
  32. 31.
    Heard BE, Cooke RA. 1968. Busulphan lung. Thorax 23:187–193.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 32.
    Green MR. 1977. Pulmonary toxicity of antineoplastic agents. West J Med 127:292–298.PubMedCentralPubMedGoogle Scholar
  34. 33.
    Tyrka AF, Skornik WA, Godleski JJ, Brain JD. 1982. Potentiation of bleomycin induced lung disease by exposure to 70% oxygen: Morphologic assessment. Am Rev Respir Dis 126:1074–1079.Google Scholar
  35. 34.
    Einhorn L, Krause M, Hornback N, Furnas B. 1976. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer 37:2414–2416.PubMedCrossRefGoogle Scholar
  36. 35.
    Manning DM, Straimlan CV, Turbiner EH. 1980. Early detection of husulfan lung: Report of a case. Clin nucl Med 5:412–414.PubMedCrossRefGoogle Scholar
  37. 36.
    MacMahon H, Bekerman C. 1978. The diagnostic significance of gallium lung uptake in patients with normal chest radiographs. Radiology 127:189–193.PubMedCrossRefGoogle Scholar
  38. 37.
    Bedrossian CWM, Greenberg SD, Yawn DH, O’Neal RM. 1977. Experimentally induced bleomycin sulfate pulmonary toxicity. Arch Pathol Lab Med 101:248–254.PubMedGoogle Scholar
  39. 38.
    Blum RH. 1974. An overview of bleomycin pulmonary toxicity. In: New drug Seminar on Bleomycin. National Cancer Institute, Bethesda, Maryland, pp 151–162.Google Scholar
  40. 39.
    Holoye PY, Luna MA, MacKay B, Bedrossian CWM. 1978. Bleomcyin hypersentitivity pnemonitis. Ann Intern Med 88:47–49.PubMedCrossRefGoogle Scholar
  41. 40.
    Perez-Guerra F, Harkleroad LE, Walsh RE, Costanzi JJ. 1972. Acute bleomycin lung. Am Rev Respir Dis 106:909–913.PubMedGoogle Scholar
  42. 41.
    Sostman HD, Matthay RA, Putman CE, Walker Smith GJ. 1976. Methotrexate induced pneumonitis. Medicine (Baltimore) 55:371–388.CrossRefGoogle Scholar
  43. 42.
    Rosenow EC III, Unni KK. 1983. Drug Induced granulomas. Lung Biol Health Dis 20:469–484.Google Scholar
  44. 43.
    Rosenow EC III, Harrison CE Jr. 1970. Congestive heart faillure masquerading as primary pulmonary disease. Chest 58:28–36.PubMedCrossRefGoogle Scholar
  45. 44a.
    Moser KM, Fedullo PF. 1983. Venous Thromboembolism: Three simple decisions. Chest 83:117–121.PubMedGoogle Scholar
  46. 44b.
    Moser KM, Fedullo PF. 1983. Venous Thromboembolism: Three simple decisions. Chest 83: 256–260.PubMedCrossRefGoogle Scholar
  47. 45.
    Barlett J, Gorbach S. 1975. The triple threat of aspiration pneumonia. Chest 68:562–566.Google Scholar
  48. 46.
    Downs J. 1974. An Evaluation of steroid therapy and aspiration pneumonitis. Anesthesiology 40:129–135.PubMedCrossRefGoogle Scholar
  49. 47.
    Fowler AA, Hamman RF, Good JT, Benson KM, Baird M, Eberle DJ, Petty Tl, Hyers TM. 1983. Adult respiratory distress syndrome: risk with commonpre-dispositions. Ann Intern Med 98:593–597.PubMedCrossRefGoogle Scholar
  50. 48.
    Popovsky MA, Abel MD, Moore SB: 1983. Transfusion related acute lung injury associated with passive transfer of anti-leukocyte antibodies. Am Rev Respir. Dis 128:185–189.PubMedGoogle Scholar
  51. 49.
    Wright DG, Robichaud KJ, Pizzo PA, Deisseroth AB. 1981. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 304, 20:1185–1189.PubMedCrossRefGoogle Scholar
  52. 50.
    Boxer LA, Ingraham LM, Allen J, Oseas RS, Baehner RL. 1981. Amphotericin B promotes leukocyte aggregation of nylon-wool-fiber-treated polymorphonuclear leukocytes. Blood 58, 3:518–23.PubMedGoogle Scholar
  53. 51.
    Clark JM, Lambertsen CJ. 1971. Pulmonary oxygen toxicity — A Review. Pharmacol Rev 23:37–133.PubMedGoogle Scholar
  54. 52.
    Reiner RR. 1982. Risk of a second malignancy related to the use of cytotoxic chemotherapy. CA 32:286–292.Google Scholar
  55. 53.
    Penn I. 1976. Second malignant neoplasms associated with immunosuppressive medications. Cancer 37:1024–1032.PubMedCrossRefGoogle Scholar
  56. 54.
    Gross NJ. 1977. Pulmonary effects of radiation therapy. Ann Intern Med 86:81–92.PubMedCrossRefGoogle Scholar
  57. 55.
    Smith JC. 1963. Radiation pneumonitis. Am Rev Respir. Dis 87:647–655.PubMedGoogle Scholar
  58. 56.
    Castellino RA, Glastein E, Turbow MM, Rosenberg S, Kaplan HS. 1974. Latent radiation injury of lungs or heart activated by steroid withdrawal. Ann Intern Med 80:593–588.PubMedCrossRefGoogle Scholar
  59. 57.
    Light RW, MacGregor I, Luchsinger PC, Ball WC. Pleural effusions: The diagnostic separation of transudate and exudates. Ann Intern Med 77:507–513.Google Scholar
  60. 58.
    Black LF. 1972. The pleural space and pleural fluid. Mayo Clin Proc 47:491–506.Google Scholar
  61. 59.
    Chernow B, Sahn SA. 1977. Carcinomatous involvement of the pleura: An analysis of 96 patients. Am J Med 63:695–702.PubMedCrossRefGoogle Scholar
  62. 60.
    Meyer PC. 1966. Metastatic carcinoma of the pleura. Thorax 21:437–443.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 61.
    Rosenow EC III. 1980. Miscellaneous drug induced pulmonary disease. Semin Respir Med 2:76–88.CrossRefGoogle Scholar
  64. 62.
    Oels H, Harrison E, Carr D. 1971. Diffuse malignant mesothelioma of the pleural: A review of 37 cases. Chest 60:565–570.CrossRefGoogle Scholar
  65. 63.
    Kwel WS, Veldhuizen RW, Goldring RD, Mullink H, Stam J, Donner R, Boon ME. 1982. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinomatous metastasis. Virchows Arch (Pathol Anat) 397:287–299.CrossRefGoogle Scholar
  66. 64.
    Boutin C, Viallat JR, Cargnino P, Farisse P. 1981. Thoracoscopy in malignant pleural effusion. Am REV Respir Dis 124:588–592.PubMedGoogle Scholar
  67. 65.
    Decker DA, Dines PE Payne WS: 1978. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Chest 74:640–642.Google Scholar
  68. 66.
    Sahn SA, Good JT JR, Potts DE. 1979. The pH of sclerosing agents: A determinate of pleural symphysis. Chest 76:198–200.PubMedCrossRefGoogle Scholar
  69. 67.
    Wallach HW. 1975. Intrapleural tetracycline for malignant effusions. Chest 68:510–512.PubMedCrossRefGoogle Scholar
  70. 68.
    Zaloznik AJ, Oswald SG, Langin M. 1983. Intrapleural tetracycline inmalignant pleural effusions: A randomized study. Cancer 51:752–755.PubMedCrossRefGoogle Scholar
  71. 69.
    Sahn SA, Good JT Jr. 1981. The effect of common sclerosing agents on the rabbit pleural space. Am Rev Respir Dis 124:65–67.PubMedGoogle Scholar
  72. 70.
    Wallach HW. 1978. Intrapleural therapy with tetracycline and lidocaine for malignant pleural effusions. Chest 73:246.PubMedCrossRefGoogle Scholar
  73. 71.
    Good JTJr, Taryle DA, Sahn SA. 1978. Pleural fluid pH in malignant effusions: Pathophysiologic and prognostic implications. Chest 74:338.CrossRefGoogle Scholar
  74. 72.
    Martini N, Bains MS, Beattie EJ Jr. 1975. Indications for pleurectomy in malignant effusions. Cancer 35:734–738.PubMedCrossRefGoogle Scholar
  75. 73.
    Butchart EG, Ashcroft, T, Barnsley WC: 1981. The role of surgery in diffuse malignant mesothelioma of the pleura. Sem. Oncol 8:321–328.Google Scholar
  76. 74.
    Beaty HN, Miller AA, Broome CV, Goings S, Phillips CA: 1978. Legionnaires’ disease in Vermont. JAMA. 240, 2:127–131.PubMedCrossRefGoogle Scholar
  77. 75.
    Fisher ED, Armstrong D. 1977. Cryptococcal interstitial pneumonitis: Value of antigen determination. NEJM 297:1440–1444.PubMedCrossRefGoogle Scholar
  78. 76.
    Pierce PF, DeYoung DR, Roberts GD. 1983. Mycobacteremia and the new blood culture systems. Ann Intern Med 99:780–789.CrossRefGoogle Scholar
  79. 77.
    Ries K, Levision Me, Kaye D. 1974. Transtracheal aspiration in pulmonary infection. Arch Intern Med 133:453–458.PubMedCrossRefGoogle Scholar
  80. 78.
    Wimberly N, Faling LJ, Bartlett JG. 1979. A fiberoptic bronchoscopy technique to obtain uncomtaminated lower airway secretions for bacterial culture. Am Rev Respir Dis 119:337–343.Google Scholar
  81. 79.
    Stover DE, Zaman MB, Hajdu SI, Lange M, Gold J, Armstrong D. 1984. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med 101:1–7.PubMedCrossRefGoogle Scholar
  82. 80.
    Kelly J, Landis JN, Davis GS, Trainer TD, Jakob GJ, Green GM. 1978. Diagnosis of pneumonia due to Pneumocystis by subsegmental pulmpnary lavage via the fibreroptic bronchoscope. Chest 74:24–28.CrossRefGoogle Scholar
  83. 81.
    Rankin JA. 1985. Bronchoalveolar lavage for research purposes in the immunocompromised host. Chest 88:319–320.PubMedCrossRefGoogle Scholar
  84. 82.
    Landis JN, Jaciow D. Personal communication.Google Scholar
  85. 83.
    Zavala DC, Schoell JE. 1981. Ultrathin needle aspiration of the lung in infectious and malignant disease. Am Rev Respir Dis 123:125–131.PubMedGoogle Scholar
  86. 84.
    Dijkman JH, van der Meer JWM, Bakken W, Wever AMJ, van der Brock PJ. 1982. RTranspleural lung biopsy by the transthoracic route in patients with diffuse interstitial pulmonary disease. Chest 82:76–83.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • John N. Landis

There are no affiliations available

Personalised recommendations